November 28, 2023
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
Amsterdam, the Netherlands
argenx SE today announced topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia (ITP). The study did not meet the primary endpoint of a sustained platelet count response in chronic ITP patients.
Get photos, fact sheets, illustrations and more.
Join the team
Dare to do more with a thriving career at argenx.
Get the latest news and info via our social media channels.